Rafferty Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,865	Closed	-$226K	–	1081
2025 Q4	$226K	Sell	4,865 -1,314	-21%	-$58.5K	﹤0.01%	1065
2025 Q3	$257K	Sell	6,179 -84,577	-93%	-$2.7M	﹤0.01%	1019
2025 Q2	$2.61M	Sell	90,756 -11,375	-11%	-$351K	0.01%	542
2025 Q1	$3.43M	Buy	102,131 +20,874	+26%	+$780K	0.01%	447
2024 Q4	$4.15M	Sell	81,257 -16,193	-17%	-$906K	0.01%	451
2024 Q3	$4.98M	Sell	97,450 -14,719	-13%	-$759K	0.02%	427
2024 Q2	$5.02M	Sell	112,169 -104,680	-48%	-$4.83M	0.02%	414
2024 Q1	$10.2M	Sell	216,849 -27,440	-11%	-$1.07M	0.04%	261
2023 Q4	$8.69M	Buy	244,289 +46,548	+24%	+$1.43M	0.04%	317
2023 Q3	$5.88M	Buy	197,741 +59,555	+43%	+$1.23M	0.03%	356
2023 Q2	$2.49M	Buy	138,186 +9,478	+7%	+$189K	0.01%	586
2023 Q1	$2.07M	Buy	128,708 +22,210	+21%	+$411K	0.01%	604
2022 Q4	$1.95M	Buy	106,498 +31,045	+41%	+$547K	0.02%	586
2022 Q3	$1.48M	Buy	75,453 +30,684	+69%	+$626K	0.02%	576
2022 Q2	$835K	Sell	44,769 -33,366	-43%	-$666K	0.01%	704
2022 Q1	$1.72M	Buy	78,135 +26,023	+50%	+$527K	0.01%	654
2021 Q4	$1.48M	Buy	52,112 +24,599	+89%	+$606K	0.01%	761
2021 Q3	$579K	Buy	+27,513	New	+$576K	﹤0.01%	1009